-
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
-
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma
-
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
-
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
-
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
-
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
